中国新药杂志

光免疫偶联物的研究进展

PDF下载

徐颖菊 ¹ , 宋玉明 ² , 路海滨 ¹

中国新药杂志 | 综述 2021,30(16): 1471-1476

收起

中国新药杂志 |综述 2021 , 30 (16) : 1471 -1476

光免疫偶联物的研究进展

全屏

[Author(id=1322180321181810692, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=2552888173@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322180321253113862, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, authorId=1322180321181810692, language=EN, stringName=Ying-ju XU, firstName=Ying-ju, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹Jilin University College of Pharmacy, Changchun 130031, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322180321320222727, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, authorId=1322180321181810692, language=CN, stringName=徐颖菊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹吉林大学　药学院，长春　130031, bio={"content":"

徐颖菊，女，硕士研究生，主要从事药物合成及活性测定的研究。E-mail：2552888173@qq.com。

"}, bioImg=null, bioContent=

徐颖菊，女，硕士研究生，主要从事药物合成及活性测定的研究。E-mail：2552888173@qq.com。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322180320993068030, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, xref=1, ext=[AuthorCompanyExt(id=1322180321001456639, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, companyId=1322180320993068030, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Jilin University College of Pharmacy, Changchun 130031, China), AuthorCompanyExt(id=1322180321005650944, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, companyId=1322180320993068030, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹吉林大学　药学院，长春　130031)])]), Author(id=1322180321412497417, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=songyuming1878@163.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322180321508966411, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, authorId=1322180321412497417, language=EN, stringName=Yu-ming SONG, firstName=Yu-ming, middleName=null, lastName=SONG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=², address=²Jilin University Department of Respiratory Medicine, China-Japan Friendship Hospital, Changchun 130031, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322180321597046796, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, authorId=1322180321412497417, language=CN, stringName=宋玉明, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=², address=²吉林大学　吉林大学中日联谊医院呼吸科，长春　130031, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322180321068564480, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, xref=2, ext=[AuthorCompanyExt(id=1322180321076953089, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, companyId=1322180321068564480, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²Jilin University Department of Respiratory Medicine, China-Japan Friendship Hospital, Changchun 130031, China), AuthorCompanyExt(id=1322180321085341698, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, companyId=1322180321068564480, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²吉林大学　吉林大学中日联谊医院呼吸科，长春　130031)])]), Author(id=1322180321668349966, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=luhaibin@jlu.edu.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322180321748041744, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, authorId=1322180321668349966, language=EN, stringName=Hai-bin LU, firstName=Hai-bin, middleName=null, lastName=LU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹Jilin University College of Pharmacy, Changchun 130031, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322180321823539217, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, authorId=1322180321668349966, language=CN, stringName=路海滨, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹吉林大学　药学院，长春　130031, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322180320993068030, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, xref=1, ext=[AuthorCompanyExt(id=1322180321001456639, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, companyId=1322180320993068030, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Jilin University College of Pharmacy, Changchun 130031, China), AuthorCompanyExt(id=1322180321005650944, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180320233899003, companyId=1322180320993068030, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹吉林大学　药学院，长春　130031)])])]

徐颖菊¹, 宋玉明², 路海滨¹

作者信息

¹吉林大学　药学院，长春　130031

²吉林大学　吉林大学中日联谊医院呼吸科，长春　130031

通讯作者:

路海滨，男，副教授，硕士生导师，主要从事药物合成及活性测定的研究。联系电话：（0431）85619252，E-mail：luhaibin@jlu.edu.cn。

宋玉明，男，副教授，硕士生导师，主要从事呼吸系统感染性疾病、肺部肿瘤、肺血栓栓塞症的诊断、治疗及相关机理的研究。联系电话：（0431）84995999，E-mail：songyuming1878@163.com。

作者简介:

徐颖菊，女，硕士研究生，主要从事药物合成及活性测定的研究。E-mail：2552888173@qq.com。

Progress in researches on photoimmunoconjugates

Ying-ju XU¹, Yu-ming SONG², Hai-bin LU¹

Affiliations

¹Jilin University College of Pharmacy, Changchun 130031, China

²Jilin University Department of Respiratory Medicine, China-Japan Friendship Hospital, Changchun 130031, China

出版时间: 2021-08-30

文章导航

摘要

收起

近年来，恶性肿瘤的发病率呈递增趋势。经过手术切除、化疗、放疗等常规的治疗手段，很多患者的病情仍未得到有效控制。因此，探寻新的治疗方式成为肿瘤防控的重点。光免疫疗法（photoimmunotherapy，PIT）在实体瘤研究中的作用越来越突出。光免疫偶联物（photoimmunoconjugate，PIC）具有肿瘤特异性识别的能力，兼具高细胞毒性。本文综述了过去10年该类新型分子靶向药物的研究进展，以卟啉、二氢卟吩e6（Ce6）、酞菁染料（IR700）等光敏剂交联单克隆抗体（monoclonal antibodies，MAbs）药物的合成及其作为光敏药物的研究结果。

关键词

光免疫疗法 / 光敏剂 / 单克隆抗体 / 光免疫偶联物

Abstract

收起

In recent years, the incidence of malignant tumors has been increasing. After conventional treatments such as surgical resection, chemotherapy, and radiotherapy, many patients' conditions are still not effectively controlled. Therefore, exploring new treatment methods has become the focus of tumor prevention and control. The role of photoimmunotherapy (PIT) in solid tumor research is becoming more and more prominent. Photoimmunoconjugate (PIC) has the ability of tumor-specific recognition and high cytotoxicity. This article reviews the progress in the development of such novel molecular targeted drugs in the past decade, and the results from the study of using porphyrin, chlorin e6 (Ce6), phthalocyanine dye (IR700) and other photosensitizer conjugated monoclonal antibodies (MAbs) as photosensitizing drugs were discussed respectively.

Key words

photoimmunotherapy / photosensitizer / monoclonal antibodies / photoimmunoconjugates

引用本文

徐颖菊, 宋玉明, 路海滨. 光免疫偶联物的研究进展. 中国新药杂志, 2021 , 30 (16) : 1471 -1476 .

Ying-ju XU, Yu-ming SONG, Hai-bin LU. Progress in researches on photoimmunoconjugates[J]. Chinese Journal of New Drugs, 2021 , 30 (16) : 1471 -1476 .

基金

收起

吉林省卫生科研人才专项项目(2019SC2062)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

BENOV L. Photodynamic therapy: current status and future directions[J]. Med Princ Pract, 2015, 24(Suppl 1): S14-S28.

[2]

VAN DONGEN GA, VISSER GW, VROUENRAETS MB. Photosensitizer-antibody conjugates for detection and therapy of cancer[J]. Adv Drug Deliv Rev, 2004, 56(1): 31-52.

[3]

ETHIRAJAN M, CHEN YH, JOSHI P, et al. The role of porphyrin chemistry in tumor imaging and photodynamic therapy[J]. Chem Soc Rev, 2011, 40(1): 340-362.

[4]

TSOLEKILE N, NELANA S, OLUWAFEMI OS. Porphyrin as diagnostic and therapeutic agent[J]. Molecules, 2019, 24(14): 2669.

[5]

MEW D, LUM V, WAT CK, et al. Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation[J]. Cancer Res, 1985, 45(9): 4380-4386.

[6]

MALATESTI N, SMITH K, SAVOIE H, et al. Synthesis and in vitro investigation of cationic 5, 15-diphenyl porphyrin-monoclonal antibody conjugates as targeted photodynamic sensitisers[J]. Int J Oncol, 2006, 28(6): 1561-1569.

[7]

SMITH K, MALATESTI N, CAUCHON N, et al. Mono- and tri-cationic porphyrin-monoclonal antibody conjugates: photodynamic activity and mechanism of action[J]. Immunology, 2011, 132(2): 256-265.

[8]

BRYDEN F, MARUANI A, SAVOIE H, et al. Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment[J]. Bioconjug Chem, 2014, 25(3): 611-617.

[9]

MARUANI A, SAVOIE H, BRYDEN F, et al. Site-selective multi-porphyrin attachment enables the formation of a next-generation antibody-based photodynamic therapeutic[J]. Chem Commun, 2015, 51(83): 15304-15307.

[10]

BRYDEN F, MARUANI A, RODRIGUES JMM, et al. Assembly of high-potency photosensitizer-antibody conjugates through application of dendron multiplier technology[J]. Bioconjug Chem, 2018, 29(1): 176-181.

[11]

ABU-YOUSIF AO, MOOR AC, ZHENG X, et al. Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells[J]. Cancer Lett, 2012, 321(2): 120-127.

[12]

LIANG BJ, PIGULA M, BAGLO Y, et al. Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting[J]. J Nanobiotechnology, 2020, 18(1): 1.

[13]

PENON O, MARÍN MJ, RUSSELL DA, et al. Water soluble, multifunctional antibody-porphyrin gold nanoparticles for targeted photodynamic therapy[J]. J Colloid Interface Sci, 2017, 496(11): 100-110.

[14]

KANG XM, GUO XM, NIU XJ, et al. Photothermal therapeutic application of gold nanorods-porphyrin-trastuzumab complexes in HER2-positive breast cancer[J]. Sci Rep, 2017, 7(1): 42069.

[15]

UCHOA AF, DE OLIVEIRA KT, BAPTISTA MS, et al. Chlorin photosensitizers sterically designed to prevent self-aggregation[J]. J Org Chem, 2011, 76(21): 8824-8832.

[16]

HUSSAIN AF, KAMPMEIER F, VON FELBERT V, et al. SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells[J]. Bioconjugate Chem, 2011, 22(12): 2487-2495.

[17]

CHANG MH, PAI CL, CHEN YC, et al. Enhanced antitumor effects of epidermal growth factor receptor targetable cetuximab-conjugated polymeric micelles for photodynamic therapy[J]. Nanomaterials (Basel), 2018, 8(2): 121.

[18]

PYE H, BUTT MA, FUNNELL L, et al. Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression[J]. Oncotarget, 2018, 9(33): 22945-22959.

[19]

KIM KS, KIM J, KIM DH, et al. Multifunctional trastuzumab-chlorin e6 conjugate for the treatment of HER2-positive human breast cancer[J]. Biomater Sci, 2018, 6(5): 1217-1226.

[20]

SEKKAT N, VAN DEN BERGH H, NYOKONG T, et al. Like a bolt from the blue: phthalocyanines in biomedical optics[J]. Molecules, 2011, 17(1): 98-144.

[21]

NAKAJIMA T, SANO K, CHOYKE PL, et al. Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model[J]. Theranostics, 2013, 3(6): 357-365.

[22]

HEUKERS R, VAN BERGEN EN HENEGOUWEN PM, OLIVEIRA S. Nanobody-photosensitizer conjugates for targeted photodynamic therapy[J]. Nanomed-Nanotechnol, 2014, 10(7): 1441-1451.

[23]

DE BOER E, SAMUEL S, FRENCH DN, et al. Biodistribution study of intravenously injected cetuximab-IRDye700DX in cynomolgus macaques[J]. Mol Imaging Biol, 2016, 18(2): 232-242.

[24]

NAGAYA T, NAKAMURA Y, SATO K, et al. Near infrared photoimmunotherapy with an anti-mesothelin antibody[J]. Oncotarget, 2016, 7(17): 23361-23369.

[25]

NAGAYA T, NAKAMURA Y, SATO K, et al. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody[J]. Oncotarget, 2017, 8(5): 8807-8817.

[26]

SHIRASU N, YAMADA H, SHIBAGUCHI H, et al. Potent and specific antitumor effect of CEA-targeted photoimmunotherapy[J]. Int J Cancer, 2014, 135(11): 2697-2710.

[27]

JING H, WEIDENSTEINER C, REICHARDT W, et al. Imaging and selective elimination of glioblastoma stem cells with theranostic near-infrared-labeled CD133-specific antibodies[J]. Theranostics, 2016, 6(6): 862-874.

[28]

ISOBE Y, SATO K, NISHINAGA Y, et al. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer[J]. EBioMedicine, 2020, 52(C): 102632.

[29]

KISS B, VAN DEN BERG NS, ERTSEY R, et al. CD47-targeted near-infrared photoimmunotherapy for human bladder cancer[J]. Clin Cancer Res, 2019, 25(12): 3561-3571.

[30]

WEI WJ, JIANG DW, EHLERDING EB, et al. CD146-targeted multimodal image-guided photoimmunotherapy of melanoma[J]. Adv Sci, 2019, 6(9): 1801237.

[31]

NAIDOO C, KRUGER CA, ABRAHAMSE H. Targeted photodynamic therapy treatment of in vitro A375 metastatic melanoma cells[J]. Oncotarget, 2019, 10(58): 6079-6095.

[32]

MAO CQ, QU P, MILEY MJ, et al. P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates[J]. Biomater Sci, 2018, 6(11): 3063-3074.

[33]

HANAOKA H, NAKAJIMA T, SATO K, et al. Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel[J]. Nanomedicine, 2015, 10(7): 1139-1147.

[34]

ITO K, MITSUNAGA M, ARIHIRO S, et al. Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms[J]. BMC Cancer, 2016, 16(1): 37.

[35]

ADIL BUTT M, PYE H, HAIDRY RJ, et al. Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate[J]. Oncotarget, 2017, 8(15): 25080-25096.

[36]

LUND K, BOSTAD M, SKARPEN E, et al. The novel EpCAM-targeting monoclonal antibody 3-17I linked to saporin is highly cytotoxic after photochemical internalization in breast, pancreas and colon cancer cell lines[J]. MAbs, 2014, 6(4): 1038-1050.

[37]

AUNG W, TSUJI AB, SUGYO A, et al. Near-infrared photoimmunotherapy of pancreatic cancer using an indocyanine green-labeled anti-tissue factor antibody[J]. World J Gastroenterol, 2018, 24(48): 5491-5504.

[38]

YE ZY, LIANG YF, MA Y, et al. Targeted photodynamic therapy of cancer using a novel gallium (Ⅲ) tris (ethoxycarbonyl) corrole conjugated-MAb directed against cancer/testis antigens 83[J]. Cancer Med, 2018, 7(7): 3057-3065.

[39]

KOCHUPARAMBIL ST, MCDONALD D, FIDLER M, et al. A phase 1, multicenter, open-label, dose-escalation, combination study of RM-1929 and photoimmunotherapy in patients with recurrent head and neck cancer[J]. Ann Oncol, 2017, 28 (Suppl 5): S376.

[40]

JOHNSON JM, COGNETTI DM, CURRY JM, et al. Integrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC)[J]. Ann Oncol, 2019, 30 (Suppl 5): S462.

[41]

TAHARA M, OKANO S, ENOKIDA T, et al. Phase 1 study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma[J]. Ann Oncol, 2019, 30 (Suppl 6): S82-S89.

[42]

LU GL, VAN DEN BERG NS, MARTIN BA, et al. Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study[J]. Lancet Gastroenterol Hepatol, 2020, 5(8): 753-764.

[43]

阚官婷, 俞建东, 熊阳. 二甲双胍联合化疗药物抗肿瘤的研究进展[J]. 中国现代应用药学, 2020, 37(16): 2025-2030.

2021年第30卷第16期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-28
出版时间：2021-08-30

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2020-12-07

基金

吉林省卫生科研人才专项项目(2019SC2062)

作者信息

¹吉林大学　药学院，长春　130031

²吉林大学　吉林大学中日联谊医院呼吸科，长春　130031

通讯作者:

路海滨，男，副教授，硕士生导师，主要从事药物合成及活性测定的研究。联系电话：（0431）85619252，E-mail：luhaibin@jlu.edu.cn。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322180320233899003

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT